EBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM‐PET‐POSITIVE ADVANCED‐STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL

EBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM‐PET‐POSITIVE ADVANCED‐STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL

Saved in:
Bibliographic Details
Published in:Hematological oncology Vol. 35; no. S2; p. 65
Main Authors: Borchmann, P., Goergen, H., Kobe, C., Eichenauer, D., Greil, R., Lohri, A., Novak, U., Markova, J., Beck, H., Meissner, J., Zijlstra, J.M., Ostermann, H., Feuring‐Buske, M., Dierlamm, J., Eich, H., Baues, C., Rosenwald, A., Fuchs, M., Diehl, V., Kuhnert, G., Dietlein, M., Engert, A.
Format: Journal Article
Language:English
Published: Chichester Wiley Subscription Services, Inc 01-06-2017
Subjects:
Hodgkin's lymphoma
Immunotherapy
Lymphoma
Monoclonal antibodies
Rituximab
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2437_52